Study On The Effects Of Combination Of Docetaxol With Arsenic Trioxide On Prostate Cancer PC-3 Lines In Vitro

Objectives:To investigate the anti-proliferation effects and mechanism of decotaxol with arsenic trioxide on hormone-refractory prostate cancer cell lines PC-3 in vitro, which may provide some clues to clinical application.Methods: 1.This study was divided into two parts.One was single agent experiment,and the other was agents combination experiment.There were three groups for single agent experiment: docetaxol,arsenic trioxide and negative control group. Cell morphology, flow cytometer, MTT method was used to observe the effect of all groups on prostate cancer cell lines PC-3 in vitro. 2.The concentrations of decotaxol and arsenic trioxide was selected for combination experimental use,which inhibition rate on PC-3 cell was from 10-30% in single used.MTT method was used to investigate the growth inhibition. The expression of Caspase-3 was determined by FCM in different groups.Results: 1)In single agent experiment, with the increasing concentration and prolonging of treatment time,arsenic trioxide and docetaxol can significantly inhibited the proliferation of PC-3 cells in a dose and time-dependent manner. MTT colorimetric method was performed to evaluate the potential cytostatic effect of combining arsenic trioxide with docetaxol.It showed that low concentration of docetaxol had the enhancing synergistic effect combined with arsenic trioxide. 2). Arsenic trioxide 1 could significantly increased the level of caspase—3 in PC-3 cells when combined with docetaxol.Conclusions: Through MTT colorimetric method,we confirmed that arsenic 'trioxide combined with docetaxel had a synergistic effect on inhibiting the proliferation of PC-3 cells. Their effects of inhibiting the proliferation of PC-3 cells seem to due to up-regulation of the expression of caspase-3.The research tirst time showed that arsenic trioxide combined with docetaxel had a synergistic effect on inhibiting the proliferation of PC-3 cells,which provided a new theoretical basement for reasonable clinical treatment of hormone- independent prostate cancer.